Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04880642 · ClinicalTrials.gov registry record · Phase 3
A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
A Phase 3 study, sponsored by Vicore Pharma AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
NCT04880642 is a Phase 3 study that has completed, run by Vicore Pharma AB. The registered enrollment target is 272 participants.
The verdict
NCT04880642, a Phase 3 study, has completed, sponsored by Vicore Pharma AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
Study Summary
This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm, multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add-on to standard of care (SoC) in adult subjects with COVID-19. The trial planned to enroll a total of maximum 300 randomized subjects, 150 per arm (oral C21 100 mg twice a day (BID) or placebo for 14 days) according to the 1:1 randomization.
Interventions
- DRUG Placebo
- DRUG C21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04880642
The ClinicalTrials.gov registry entry for NCT04880642 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vicore Pharma AB, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04880642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04880642 about?
NCT04880642 is a clinical study titled "A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects". This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm, multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add-on to standard of care (SoC) in adult subjects with COVID-19. The trial planned to enroll a total of maximum 300 randomized subject...
What is the current status of trial NCT04880642?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2021-09-16. Estimated completion is 2022-04-25.
What interventions are being tested in trial NCT04880642?
The interventions under investigation include: Placebo (DRUG), C21 (DRUG).
Who is sponsoring clinical trial NCT04880642?
This trial is sponsored by Vicore Pharma AB, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.